Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leading biopharmaceutical company focused on the development and commercialization...Read more
First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety profile More than half of TREMFYA®-treated patients across both dose groups...Read more
Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived tau following buntanetap...Read more
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration...Read more
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 WESTLAKE VILLAGE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Arcutis...Read more
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment. PHILADELPHIA,...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Jazz Pharmaceuticals | 29.02 20.57 | $170.09 |
| Madrigal Pharmaceuticals | 24.21 4.57 | $553.42 |
| argenx | 21.63 2.38 | $929.61 |
| McKesson | 13.14 1.56 | $855.23 |
| Ascendis Pharma | 12.16 5.95 | $216.56 |
| Nuvalent | 11.50 11.92 | $108.00 |
| Alnylam Pharmaceuticals | 11.38 2.53 | $460.54 |
| Praxis Precision Medicines | 11.16 5.99 | $197.58 |
| Regeneron Pharmaceuticals | 10.81 1.56 | $704.31 |
| Movano Health | 7.04 226.37 | $10.15 |
| Axsome Therapeutics | 5.87 4.20 | $145.56 |
| United Therapeutics | 5.52 1.18 | $471.92 |
| Zymeworks | 5.31 28.67 | $23.83 |
| GRAIL | 5.31 6.67 | $84.94 |
| PACS Group | 5.12 48.39 | $15.70 |
| Elevance Health | 5.08 1.56 | $330.91 |
| Seres Therapeutics | 4.98 29.89 | $21.64 |
| Amgen | 4.97 1.48 | $341.71 |
| Company | Volume | Last Trade |
|---|---|---|
| Applied Therapeutics | 877,354,174 | $0.29 |
| Autonomix Medical | 738,667,319 | $1.13 |
| Galmed Pharmaceuticals | 366,215,094 | $1.07 |
| MSP Recovery | 343,492,439 | $0.53 |
| Pfizer | 76,751,930 | $25.08 |
| Clearmind Medicine | 70,570,537 | $0.28 |
| Annovis Bio | 43,850,930 | $3.00 |
| Zymeworks | 42,610,158 | $23.83 |
| Humacyte | 41,438,289 | $1.13 |
| Repare Therapeutics | 40,438,840 | $2.16 |
| Invivyd | 38,714,888 | $2.83 |
| Incannex Healthcare | 28,983,856 | $0.34 |
| Recursion | 24,613,834 | $4.15 |
| Plus Therapeutics | 23,946,698 | $0.48 |
| OneMedNet | 22,927,623 | $1.35 |
| Iovance Biotherapeutics | 20,684,850 | $2.42 |
| Outlook Therapeutics | 20,427,667 | $1.77 |
| Sangamo Therapeutics | 19,365,119 | $0.41 |
| Fractyl Health | 19,019,976 | $1.44 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
